Algorx Pharmaceuticals Inc (NASDAQ:AGRX) Institutional Investors Sentiment Index Up in Q4 2016

June 20, 2017 - By Ellis Scott

 Algorx Pharmaceuticals Inc (NASDAQ:AGRX) Institutional Investors Sentiment Index  Up in  Q4 2016

Sentiment for Algorx Pharmaceuticals Inc (NASDAQ:AGRX)

Algorx Pharmaceuticals Inc (NASDAQ:AGRX) institutional sentiment increased to 2.13 in Q4 2016. Its up 0.72, from 1.41 in 2016Q3. The ratio increased, as 32 hedge funds started new or increased equity positions, while 15 decreased and sold stakes in Algorx Pharmaceuticals Inc. The hedge funds in our partner’s database now have: 21.88 million shares, down from 21.99 million shares in 2016Q3. Also, the number of hedge funds holding Algorx Pharmaceuticals Inc in their top 10 equity positions was flat from 3 to 3 for the same number . Sold All: 1 Reduced: 14 Increased: 23 New Position: 9.

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The company has market cap of $110.52 million. The Firm is focused in the development and commercialization of prescription contraceptive products. It currently has negative earnings. The Firm has developed a transdermal patch technology, called Skinfusion.

The stock increased 6.54% or $0.24 during the last trading session, reaching $3.91. About shares traded. Agile Therapeutics Inc (NASDAQ:AGRX) has declined 48.71% since June 20, 2016 and is downtrending. It has underperformed by 65.41% the S&P500.

Caxton Corp holds 41.3% of its portfolio in Agile Therapeutics Inc for 2.12 million shares. Proquest Associates Iv Llc owns 5.06 million shares or 8.17% of their US portfolio. Moreover, Aisling Capital Llc has 2.39% invested in the company for 1.80 million shares. The Sweden-based Investor Ab has invested 1.46% in the stock. Alpinvest Partners B.V., a Netherlands-based fund reported 27,693 shares.#img1#

Agile Therapeutics Inc (NASDAQ:AGRX) Ratings Coverage

Ratings analysis reveals 100% of Agile Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Agile Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. AGRX was included in 2 notes of analysts from December 30, 2015. Cantor Fitzgerald initiated the shares of AGRX in report on Friday, January 8 with “Buy” rating. The company was initiated on Wednesday, December 30 by Noble Financial.

More notable recent Agile Therapeutics Inc (NASDAQ:AGRX) news were published by: which released: “Agile Therapeutics to Present at Noble Capital Markets’ Thirteenth Annual …” on January 19, 2017, also with their article: “FBR lists prime takeover candidates in biotech” published on March 06, 2017, published: “How a Birth Control Patch Hurt Agile Therapeutics’ Stock” on January 04, 2017. More interesting news about Agile Therapeutics Inc (NASDAQ:AGRX) were released by: and their article: “BRIEF-Agile Therapeutics reports Q1 loss per share $0.26” published on May 08, 2017 as well as‘s news article titled: “Agile Therapeutics: No Reason For The FDA To Approve Another Inferior Patch” with publication date: May 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.